Compare Amylx Pharmaceuticals Inc (AMLX) vs Schlumberger NV (SLB) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amylx Pharmaceuticals Inc vs Schlumberger NV — how do they compare? Amylx Pharmaceuticals Inc trades at $17.77 (market cap $1.98B), while Schlumberger NV trades at $48.08 (market cap $71.40B). The key difference: Schlumberger NV is far larger — about 36.1× Amylx Pharmaceuticals Inc's market cap, and Schlumberger NV pays a 2.47% dividend while Amylx Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AMLX | SLB | |
|---|---|---|
Market Cap | $1.98B | $71.40B |
Sector | Health | Energy |
52-Week High | $18.70 | $58.01 |
52-Week Low | $7.64 | $31.72 |
Enterprise Value | $1.70B | $79.62B |
Dividend Yield | — | 2.47% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMLX trades at $17.77, down 3.32% today, with a bullish technical signal from moving averages and strong analyst support. The company is in a pivotal phase with key Phase 3 data for avexitide expected in Q3 2026, targeting a potential 2027 launch. Financially, it shows significant losses with negative ROE and ROA, but cash flow from financing activities provides runway. Recent news highlights clinical progress and conference presentations, alongside ongoing class action settlement discussions.
The outlook hinges on successful clinical trial outcomes, particularly avexitide's Phase 3 readout, which could drive substantial upside toward the $30.50 consensus price target. However, high execution risk, persistent cash burn, and legal overhangs pose threats to near-term stability. Investor sentiment remains cautiously optimistic given the 90.9% buy rating from analysts, but the stock is speculative until profitability milestones are achieved.
SLB trades at $47.76, up 1.1% with a bullish technical signal despite recent volatility. The company reported Q1 2026 EPS of $0.52, beating expectations, and maintains strong cash flow from operations at $6.49B. Recent news highlights a seven-year Kuwait contract expansion and digital marketplace launch, supporting growth prospects amid oil price fluctuations.
Outlook: Analyst consensus is bullish with an $62.14 price target (30% upside). Risks include oil price sensitivity and Middle East exposure, but digital transformation and contract wins provide stability. Valuation metrics (P/E 21.04, P/S 1.95) appear reasonable relative to historical performance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amylx Pharmaceuticals Inc
Amylyx Pharmaceuticals is a biopharmaceutical firm focused on developing therapies for rare diseases. Its pipeline includes treatments for conditions like post-bariatric hypoglycemia and congenital hyperinsulinism.
Read more on AMLX →About Schlumberger NV
Schlumberger is the largest oilfield service firm in the world, with expertise in myriad disciplines, including reservoir performance, well construction, production enhancement, and more recently, digital solutions. It maintains a reputation as one of the industry's leading innovators, which has earned it dominant share in numerous end markets.
Read more on SLB →
